CD8A and cancer: Xie et al. found that USP8 could promote the progression of cancers and the exhaustion of CD8 + T cell by deubiquitinating TβRII and USP8 inhibitors could simultaneously suppress the cancer progression and improve the efficacy of cancer immunotherapy [40].